Better yet, perhaps we need to help educate this "reporter" as to the real drugs showing real results, not just "8 of 11 patients" in an experiment with no control group. She clearly did not do her homework in any kind of depth more than a 3rd grade book report. I would have expected better from the NY Times.

Her email address is: apoorva.mandavilli@nytimes.com

Anyone have a reason why I should NOT write to her and enlighten her a bit in connection with a drug that the FDA is already very excited about and the two trials that are about to close and present hard data?